Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
Abroad (travel likely)RecruitingPHASE3
Conditions
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Sanford Worthington Medical Center, Worthington, Minnesota, United States
Contact: Principal Investigator (Steven Powell, M.D.)Saint Luke's Hospital, Kansas City, Missouri, United States
Washington University School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Douglas Adkins, M.D.)Peter Oppelt, M.D. (Sub-investigator)Esther Lu, Ph.D. (Sub-investigator)Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States
Contact: Principal Investigator (Daniel Almquist, M.D.)Sanford Medical Center, Sioux Falls, South Dakota, United States
Contact: Principal Investigator (Steven Powell, M.D.)
Study leads
Douglas Adkins, M.D.
Principal Investigator
Washington University School of Medicine